Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Daily News

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Michael O'Riordan

December 07, 2020

News Conference News AHA 2020

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Michael O'Riordan

November 19, 2020

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

Todd Neale

November 15, 2020

News Conference News AHA 2020

Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm

Todd Neale

November 13, 2020

News Daily News

More Teamwork, Coordination Could Boost CV Studies in COVID-19

Shelley Wood

October 28, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

News Conference News ESC 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Michael O'Riordan

September 01, 2020

News Daily News

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

Michael O'Riordan

August 20, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Features

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Shelley Wood

July 20, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

A secondary analysis from ASPREE sets up two large RCTs testing statins in an elderly primary-prevention population.

News Daily News

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Michael O'Riordan

July 06, 2020

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

L.A. McKeown

June 08, 2020

News Daily News

COVID-19 Upset: Researchers Retract Lancet, NEJM Papers on Hydroxychloroquine, ACEi/ARBs

Michael O'Riordan

June 04, 2020

News Daily News

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Yael L. Maxwell

May 21, 2020

Advertisement

Funding the Future: How Industry Support for CV Trials Could Evolve

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm

More Teamwork, Coordination Could Boost CV Studies in COVID-19

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

COVID-19 Upset: Researchers Retract Lancet, NEJM Papers on Hydroxychloroquine, ACEi/ARBs

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content